



FINAL REPORT

Test Facility Study No. 20256434

Sponsor Reference No. RN9391R58

**A Combined Fertility and Developmental Study (Including Teratogenicity
and Postnatal Investigations) of BNT162b1, BNT162b2 and BNT162b3 by
Intramuscular Administration in the Wistar Rat**

GLP Study

SPONSOR:
BioNtech SE
12 An der Goldgrube
Mainz, 55131
Germany

TEST FACILITY:



TABLE OF CONTENTS

LIST OF FIGURES	5
LIST OF TABLES.....	6
LIST OF APPENDICES.....	7
QUALITY ASSURANCE STATEMENT	8
GLP COMPLIANCE STATEMENT AND REPORT APPROVAL	9
1. RESPONSIBLE PERSONNEL.....	10
2. ABSTRACT	11
3. INTRODUCTION.....	13
4. MATERIALS AND METHODS	14
4.1. Test Materials.....	14
4.1.1. Test Items Characterization	14
4.1.2. Test Material Identification.....	14
4.2. Reserve Samples	15
4.3. Test Items Inventory and Disposition.....	15
4.4. Dose Dispensing and Analysis.....	15
4.4.1. Preparation of Formulations	15
4.4.2. Sample Collection and Analysis	15
4.5. Test System.....	16
4.5.1. Receipt	16
4.5.2. Justification for Test System and Number of Animals.....	16
4.5.3. Animal Identification (F0 Males and F0 Females).....	16
4.5.4. Environmental Acclimation.....	16
4.5.5. Selection, Assignment, Replacement, and Disposition of Animals.....	16
4.5.6. Husbandry	17
4.6. Experimental Design.....	18
4.6.1. Administration of Test Materials.....	19
4.6.2. Justification of Route and Dose	19
4.7. In-Life Procedures, Observations, and Measurements	19
4.7.1. Mortality/Moribundity Checks	19
4.7.2. Clinical Observations.....	19
4.7.3. Body Weights.....	20
4.7.4. Food Consumption.....	20
4.7.5. Estrous Cycles.....	20
4.7.6. Mating.....	20

4.8.	Pregnancy and Parturition (Littering Subgroup Females)	21
4.9.	Litter Data (Littering Subgroup Females).....	21
4.10.	Antibody Evaluation	21
4.10.1.	Antibody Sample Collection.....	21
4.10.2.	Antibody Sample Processing	22
4.10.3.	Antibody Analysis by Microneutralization CPE-Based	22
4.11.	Terminal Procedures	23
4.11.1.	Unscheduled Deaths.....	23
4.11.2.	Scheduled Euthanasia	23
4.11.3.	Necropsy	23
4.11.4.	Fetal Examination (Caesarean-Section).....	24
5.	STATISTICAL ANALYSIS	24
5.1.	Constructed Variables.....	25
5.2.	Descriptive Statistical Analyses.....	26
5.3.	Inferential Statistical Methods	26
5.4.	Parametric/Non-Parametric.....	27
5.5.	Non-Parametric	27
5.6.	Incidence	27
6.	COMPUTERIZED SYSTEMS	28
7.	RETENTION AND DISPOSITION OF RECORDS, SAMPLES, AND SPECIMENS	28
8.	RESULTS.....	30
8.1.	Serum Antibody Analysis.....	30
8.2.	Mortality	30
8.3.	Clinical Observations.....	30
8.4.	Body Weight.....	31
8.5.	Food Consumption.....	31
8.6.	Estrous Cycle Data.....	31
8.7.	Maternal Mating Performance and Fertility	32
8.8.	Caesarean Data.....	32
8.8.1.	Gravid Uterus Weight.....	32
8.8.2.	Pregnancy Incidence	32
8.8.3.	Pre-Implantation Data.....	33
8.8.4.	Post-Implantation Data	33
8.8.5.	Fetal Data	33

8.9.	Fetal Examinations.....	33
8.9.1.	External Observations.....	33
8.9.2.	Visceral Observations.....	34
8.9.3.	Skeletal Observations.....	34
8.10.	Delivery and Litter Data.....	34
8.10.1.	Parturition and Gestation Length.....	34
8.10.2.	Pre-Birth Loss.....	35
8.10.3.	Pup Viability and Litter Sizes.....	35
8.10.4.	Pup Clinical Observations.....	35
8.10.5.	Pup Weights.....	36
8.10.6.	Pup Physical and Functional Development.....	36
8.10.7.	Pup Necropsy Findings.....	36
8.11.	Necropsy Findings of Adult Females.....	36
9.	INTEGRATED SUMMARY AND DISCUSSION OF RESULTS.....	37
10.	CONCLUSION.....	38
11.	REFERENCES.....	39
	EXPLANATION PAGE.....	40
	FIGURES.....	45
	TABLES.....	54
	APPENDICES.....	114

LIST OF FIGURES

Figure 1 Mean Pre-Mating Body Weight of Females 46
Figure 2 Mean Gestation Body Weights 47
Figure 3 Mean Lactation Body Weights 48
Figure 4 Mean Pre-Mating Food Consumption of Females..... 49
Figure 5 Mean Gestation Food Consumption 50
Figure 6 Mean Lactation Food Consumption..... 51
Figures 7a and 7b Mean Pup Body Weights..... 52

LIST OF TABLES

Table 1	Summary Pre-Mating Clinical Observations of Females	55
Table 2	Summary Gestation Clinical Observations	57
Table 3	Summary Lactation Clinical Observations	59
Table 4	Mean Pre-Mating Body Weight of Females	64
Table 5	Mean Pre-Mating Body Weight Change of Females	68
Table 6	Mean Gestation Body Weight.....	72
Table 7	Mean Gestation Body Weight Change	74
Table 8	Mean Lactation Body Weight.....	76
Table 9	Mean Lactation Body Weight Change.....	78
Table 10	Mean Pre-Mating Food Consumption of Females.....	80
Table 11	Mean Gestation Food Consumption	81
Table 12	Mean Lactation Food Consumption.....	83
Table 13	Mean Estrous Cycle Data.....	85
Table 14	Summary of Cohabitation Data and Maternal Performance.....	87
Table 15	Mean Gravid Uterus Weight and Maternal Body Weight Change.....	88
Table 16	Mean Caesarean Section Data	89
Table 17	Summary of Foetal External, Visceral and Skeletal Observations	91
Table 18	Summary of Delivery and Litter Data	100
Table 19	Mean Pup Body Weight.....	104
Table 20	Summary of Reflex and Physical Development	109
Table 21	Summary of Maternal Macroscopic Observations	110

LIST OF APPENDICES

Appendix 1	Study Plan, Last Amendment to Study Plan and Deviations.....	115
	Study Plan.....	115
	Last Amendment to Study Plan	140
	Deviations	167
Appendix 2	Certificates of Analysis.....	168
Appendix 3	Formulation Homogeneity	179
Appendix 4	Individual Mortality	187
Appendix 5	Individual Pre-Mating Clinical Observations of Females	193
Appendix 6	Individual Gestation Clinical Observations	225
Appendix 7	Individual Lactation Clinical Observations	243
Appendix 8	Individual Clinical Observations of Excluded Females.....	270
Appendix 9	Individual Pre-Mating Body Weight and Body Weight Change of Females.....	274
Appendix 10	Individual Gestation Body Weight and Body Weight Change.....	322
Appendix 11	Individual Lactation Body Weight and Body Weight Change	346
Appendix 12	Individual Pre-Mating Food Consumption of Females	370
Appendix 13	Individual Gestation Food Consumption.....	382
Appendix 14	Individual Lactation Food Consumption	394
Appendix 15	Individual Estrous Cycle Data	402
Appendix 16	Individual Mating Performance	426
Appendix 17	Individual Gravid Uterus Weight and Maternal Body Weight Change.....	438
Appendix 18	Individual Caesarean Section Data	446
Appendix 19	Individual Foetal Weight and Status.....	462
Appendix 20	Individual Foetal External Observations	481
Appendix 21	Individual Foetal Visceral Observations.....	541
Appendix 22	Individual Foetal Skeletal Observations	614
Appendix 23	Individual Delivery and Litter Data	714
Appendix 24	Individual Pup Body Weights.....	722
Appendix 25	Individual Physical, Reflex and Functional Development	796
Appendix 26	Serum Antibody Analysis	820
Appendix 27	Individual Maternal Macroscopic Observations.....	849
Appendix 28	Individual Pup Macroscopic Observations	1025
Appendix 29	Historical Control Data	1084
	Historical Control Data from Wistar Rat (CRL Lyon).....	1084
	Historical Control Data from Wistar Rat (CRL Den Bosch).....	1109
	Historical Control Data from Wistar Rat (CRL Horsham).....	1114
	Historical Control Data from Sprague Dawley Rat (CRL Horsham).....	1128

QUALITY ASSURANCE STATEMENT


This study has been audited by Quality Assurance in accordance with the applicable Good Laboratory Practice regulations. Reports were submitted in accordance with Standard Operating Procedures as follows:

QA INSPECTION DATES

Date(s) of Audit	Phase(s) Audited	Dates Findings Submitted to:	
		Study Director	Study Director Management
29-Jun-2020 – 30-Jun-2020	Final Study Plan	30-Jun-2020	30-Jun-2020
23-Jul-2020	Study Plan Amendment 01	23-Jul-2020	23-Jul-2020
02-Oct-2020	Study Plan Amendment 02	02-Oct-2020	02-Oct-2020
14-Sep-2020	Physical development	14-Sep-2020	14-Sep-2020
23-Nov-2020 – 04-Dec-2020	Report Tables	04-Dec-2020	04-Dec-2020
23-Nov-2020 – 04-Dec-2020	Report – Materials and Methods	04-Dec-2020	04-Dec-2020
23-Nov-2020 – 04-Dec-2020	Data Review – Formulations	04-Dec-2020	04-Dec-2020
23-Nov-2020 – 04-Dec-2020	Data Review – Technical Operations	04-Dec-2020	04-Dec-2020
23-Nov-2020 – 04-Dec-2020	Data Review – Clinical Pathology	04-Dec-2020	04-Dec-2020
23-Nov-2020 – 04-Dec-2020	Data Review – Necropsy	04-Dec-2020	04-Dec-2020
23-Nov-2020 – 04-Dec-2020	Report	04-Dec-2020	04-Dec-2020
07-Dec-2020 - 10-Dec-2020	Report - Results	10-Dec-2020	10-Dec-2020

In addition to the above-mentioned audits, process-based and routine facility inspections were also conducted during the course of this study. Inspection findings, if any, specific to this study were reported by Quality Assurance to the Study Director and Management and listed as a Phase Audit on this Quality Assurance Statement.

The Final Report has been reviewed to assure that it accurately describes the materials and methods, and that the reported results accurately reflect the raw data.



Quality Assurance Auditor

GLP COMPLIANCE STATEMENT AND REPORT APPROVAL

The study was performed in accordance with OECD Principles of Good Laboratory Practice as required in Directive 2004/10/EC of the European Parliament and of the Council of 11 February 2004, Bonnes Pratiques de Laboratoire, Ministère de l'Emploi et de la Solidarité Française, No. 2000/5bis, arrêté du 14/03/2000.

OECD Principles of Good Laboratory Practice are accepted by Regulatory Authorities throughout the European Union, United States of America (FDA and EPA), and Japan (MHLW, MAFF, and METI) and other countries that are signatories to the OECD Mutual Acceptance of Data Agreement.

Exceptions from the above regulations are listed below.


- Antibody analysis ([Appendix 26](#)) was not conducted in compliance with GLP but in accordance with the Good Clinical Laboratory Practice (GCLP). This Test site was selected by the Sponsor because it has the most appropriate experience concerning the measurement of neutralizing antibody titres against the SARS-CoV-2 live virus by Microneutralization CPE-based method. The delegated phase for antibody analysis was fit for purpose, performed in adherence to the facilities SOPs and working instructions, by a research facility with proper expertise, and adequate history and by individuals specially trained in this technique (according to VisMederi management of personnel procedure). This exception did not adversely affect the outcome or interpretation of this study because the methods included appropriate controls to provide reliable data and analyses according to data integrity principles and local QA Report review will ensure compliance to internal procedures.



Study Director

1. RESPONSIBLE PERSONNEL

Role/Phase		Name	Contact Information
Study Director		[REDACTED] PhD	[REDACTED]
Test Facility Management		[REDACTED] General Director	[REDACTED]
Test Facility QAU		[REDACTED] MSc, Chemical Engineer	[REDACTED]



2. ABSTRACT

The objective of this study was to assess the potential effects of BNT162b1, BNT162b2 and BNT162b3, vaccine development candidates to prevent Covid-19, and the concomitant immune response, on fertility and pre and postnatal development in the female Wistar (CRL:WI[Han]) rat.

BNT162b1, BNT162b2 and BNT162b3 were administered intramuscularly (IM) to F0 female Wistar rats 21 and 14 days before the start of mating (M-21 and M-14, respectively) and then on Gestation Day (GD) 9 and GD20, for a total of 4 dose days. A separate control group was administered saline by the same route and regimen. Each dose group consisted of 44 F0 females, 22 rats assigned to the caesarean subgroup, and 22 rats assigned to the littering subgroup. Each dose consisted of 30 µg mRNA /dosing day (0.06 mL/dose) IM injection in alternating quadriceps muscles.

Following completion of a mating phase with untreated males, 22 rats per group (nominally) underwent caesarean section on GD21 and were submitted to routine embryo-fetal development evaluations (caesarean subgroup). The remaining 22 rats per group (nominally) were allowed to litter and development of the offspring was observed up to weaning on Postnatal Day (PND) 21 (littering subgroup).

The following parameters and end points were evaluated in all F0 animals: Survival, clinical signs, body weights, body weight gains, food consumption, estrous cycles, mating performance, fertility and macroscopic observations. F0 females assigned to the caesarean subgroup were further examined for ovarian and uterine contents, gravid uterine weights and fetuses were evaluated for viability, sex, body weights, and external, visceral, and skeletal morphology. F0 females assigned to the littering subgroup were allowed to deliver naturally, and were further assessed for parturition, lactation, and maternal behavior, and were monitored to the day of euthanasia on Lactation Day (LD) 21. F1 offspring were assessed for survival, clinical signs, body weights, physical development (pinna unfolding and eye opening), preweaning auditory and visual function tests to screen for normal neurodevelopment, and macroscopic observations.

Blood samples were collected before administration of the first dose (baseline) and on the first day of cohabitation for each F0 female (both subgroups), on GD21 (caesarean subgroup), and on LD21 (littering subgroup females). Blood samples were also collected on GD21 from viable fetuses in each available litter (caesarean subgroup) and on PND21 from pups from each available litter (littering subgroup). Blood samples were evaluated for neutralizing antibody titres against SARS-CoV-2 live virus.

There were no deaths throughout the study related to any of the 3 vaccine candidates.

Intramuscular administration of BNT162b1, BNT162b2 and BNT162b3, before and during gestation to female Wistar rats resulted in non-adverse clinical signs and macroscopic findings localized to the injection site as well as transient, non-adverse body weight and food consumption effects after each dose administration. These maternal findings are all consistent with administration of a vaccine and an inflammatory/immune response.

There were no effects on estrous cycles, pre-coital interval, mating, fertility and pregnancy index, or on any ovarian, uterine, or litter parameters, including F1 pre and postnatal survival, growth, external, visceral, and skeletal morphology, or effects on pre-weaning physical and functional development of the F1 pups related to any of the 3 vaccine candidates.


Administration of 4 doses (2 prior to mating and 2 during gestation) of BNT162b1, BNT162b2, or BNT162b3 elicited SARS-CoV-2 neutralizing antibody responses in the majority of females just prior to mating (M0), at the end of gestation (GD21), and at the end of lactation (LD21). SARS-CoV-2 neutralizing titers were detected in most offspring (fetuses on GD21 and pups on PND21). SARS-CoV-2 neutralizing antibody titers were not observed in animals prior to vaccine administration or in saline-administered control animals.

In conclusion, intramuscular administration of BNT162b1, BNT162b2 and BNT162b3 before and during gestation to female Wistar (CRL:WI[Han]) rats was associated with non-adverse effects (body weight, food consumption and effects localized to the injection site) after each dose administration. There were no effects of any of the 3 vaccine candidates on mating performance or fertility in F0 female rats or on embryo-fetal or postnatal survival, growth, or development of the F1 offspring. An immune response was confirmed in F0 female rats following administration of each vaccine candidate and these responses were also detectable in the F1 offspring (fetuses and pups).

3. INTRODUCTION

The objective of this study was to assess the potential effects of BNT162b1, BNT162b2 and BNT162b3, vaccine development candidates to prevent Covid-19, and the concomitant immune response, on fertility and pre and postnatal development in the female Wistar (CRL:WI[Han]) rat.

The design of this study was based on Guidelines from the International Conference on Harmonization, S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals; Department of Health and Human Services, Food and Drug Administration (FDA), 2006 Guidance on Developmental Toxicity Studies in Vaccines for Infectious Disease Indications; WHO guidelines on nonclinical evaluation of vaccines.



FOI 2289

Pages 14-37 have been removed under section 47 of the FOI Act.

10. CONCLUSION

Intramuscular administration of BNT162b1, BNT162b2 and BNT162b3 before and during gestation to female Wistar (CRL:WI[Han]) rats was associated with non-adverse effects (body weight, food consumption and effects localized to the injection site) after each dose administration. There were no effects of any of the 3 vaccine candidates on mating performance or fertility in F0 female rats or on embryo-fetal or postnatal survival, growth, or development of the F1 offspring.

An immune response was confirmed in F0 female rats following administration of each vaccine candidate and these responses were also detectable in the F1 offspring (fetuses and pups).

FOI 2289

Pages 39-1,145 have been removed under section 47 of the FOI Act.